Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Joanna E Brewer"'
Autor:
Alan D. Bennett, Barbara Tavano, Sara Brett, Manoj Saini, Adriano Quattrini, David J. Figueroa, Katherine L Crossland, Terri V Cornforth, Cedrik M. Britten, Joanna E. Brewer, Caitriona O'Connor, Jonathan D. Silk, Dylan Steiner, Alistair G Rust, Andrew B. Gerry, Ryan Wong, Katherine Adams, Joseph P. Sanderson, Annette Pachnio, Carlos E Peredo, Preetha Viswanathan, Junping Jing, Rachel J. M. Abbott, Guy E. Wiedermann, Laura L. Quinn, Lea Patasic, Bent K. Jakobsen
Publikováno v:
The Journal of Immunology. 208:169-180
Adoptive T cell therapy with T cells expressing affinity-enhanced TCRs has shown promising results in phase 1/2 clinical trials for solid and hematological tumors. However, depth and durability of responses to adoptive T cell therapy can suffer from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c2e78d7f1803cc7f793de4dea9cfdab
https://doi.org/10.4049/jimmunol.2001357
https://doi.org/10.4049/jimmunol.2001357
Autor:
Emma Gostick, David Price, Rebecca Ashfield, Joanna E. Brewer, Marco A. Purbhoo, Brendan J. Classon, Bruno Laugel, Bent K. Jakobsen, Brian Cameron, Deborah H. Sutton, Anita Milicic, Yi Li, Andrew K. Sewell, Ruth Moysey, Emma Baston, Nathaniel Liddy, Giovanna Bossi, Alan D. Bennett
Publikováno v:
Molecular Cancer Therapeutics. 6:2081-2091
Tumor-associated human telomerase reverse transcriptase (hTERT) is expressed in >85% of human tumors but not in most normal cells. As a result, this antigen has received considerable attention from those interested in cancer immunotherapy. Specifical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f092980eb1fa31069d763c01eacd2f17
https://doi.org/10.1158/1535-7163.mct-07-0092
https://doi.org/10.1158/1535-7163.mct-07-0092
Autor:
Laszlo Radvanyi, Achim A. Jungbluth, Stanley R Frankel, Adrian Bot, Zelig Eshhar, Yoav Peretz, Kai W. Wucherpfennig, Paul F Robbins, Emma Hickman, Carlos A. Ramos, Richard A. Morgan, Joanna E Brewer
Publikováno v:
Journal for Immunotherapy of Cancer
Investigators from academia and industry gathered on August 14, 2014, in Boston at the Inaugural ImVacS conference entitled “Target Discovery for T Cell Therapy: Next Step to Advance Immunotherapies”. Novel targets, discovery strategies and enabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e23e2253f48cefa65845430f96539838
http://europepmc.org/articles/PMC4509692
http://europepmc.org/articles/PMC4509692
Autor:
Carl H. June, Edward A. Stadtmauer, Sunita Philip, Nicholas J. Pumphrey, Saul Yanovich, Tom Holdich, Bent K. Jakobsen, Lilliam Ribeiro, Alan D. Bennett, Helen K. Tayton-Martin, Joanna E. Brewer, Andrew B. Gerry, Dan T. Vogl, Irina Kulikovskaya, Luca Melchiori, Minnal Gupta, Gwendolyn Binder-Scholl, Alfred L. Garfall, Olga Goloubeva, Naseem Kerr, Michael Kalos, Sanjoy K. Sinha, Sandra Westphal, Ashraf Badros, Aaron P. Rapoport, Shari Kronsberg, Simon F. Lacey, Brendan M. Weiss, Jean A. Yared, Jeffrey Finklestein, Bruce L. Levine, Daniel Williams, Nancy M. Hardy, Don L. Siegel, Sarah Bond
Publikováno v:
Nature medicine
Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Herein we report results of a phase I/II trial to evaluate the safety and activity of autologous T-cells engineered to express an affinity-enhanced T-cell receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3a45fc72763ba8e43e24864603d2890
https://pubmed.ncbi.nlm.nih.gov/26289313
https://pubmed.ncbi.nlm.nih.gov/26289313
Autor:
Alan D. Bennett, Joanna E. Brewer, Namir J. Hassan, Gerald P. Linette, Leslie A. Litzky, Gwendolyn Binder-Scholl, Helen K. Tayton-Martin, Michael Kalos, Patrick J. Cimino, Nick Pumphrey, Edward A. Stadtmauer, Adam Bagg, Aaron P. Rapoport, Bruce L. Levine, Marcela V. Maus, Joseph Dukes, Dominic P. Smethurst, Carl H. June, Bent K. Jakobsen, Jane Harper, Lyndsey Emery, Beatriz M. Carreno, Andrew B. Gerry
An obstacle to cancer immunotherapy has been that the affinity of T-cell receptors (TCRs) for antigens expressed in tumors is generally low. We initiated clinical testing of engineered T cells expressing an affinity-enhanced TCR against HLA-A*01–re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6db4b1b764b63316916d1897b42a8b11
https://europepmc.org/articles/PMC3743463/
https://europepmc.org/articles/PMC3743463/
Autor:
Giovanna Bossi, Minnal Gupta, Brian Cameron, Alison Legg, Namir J. Hassan, Daniel Williams, Vivekanandan Kannan, Francis Grand, Edward A. Stadtmauer, Frayne Bianchi, Nicholas J. Pumphrey, Gwendolyn Binder-Scholl, Jane Harper, Bent K. Jakobsen, Alan D. Bennett, Michael Kalos, James L. Riley, Angel Varela-Rohena, Joanna E. Brewer, Alex Powlesland, Andrew B. Gerry, Gabriela Plesa, Joseph Dukes, Carl H. June, Bruce L. Levine, Annelise Vuidepot, Irina Kulikovskaya, Gerald P. Linette, Aaron P. Rapoport, Katherine Adams
Publikováno v:
Science Translational Medicine. 5
MAGE A3, which belongs to the family of cancer-testis antigens, is an attractive target for adoptive therapy given its reactivation in various tumors and limited expression in normal tissues. We developed an affinity-enhanced T cell receptor (TCR) di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b0e1b31096446558c5e434ade9ee2a9
https://doi.org/10.1126/scitranslmed.3006034
https://doi.org/10.1126/scitranslmed.3006034
Autor:
Nicholas J. Pumphrey, Katherine Adams, Alan D. Bennett, Bent K. Jakobsen, Joanna E. Brewer, Andrew B. Gerry
Publikováno v:
Cancer Research. 74:2801-2801
Engineering T cells with enhanced affinity T cell receptors (TCRs) is a promising therapeutic strategy for treating cancer. Engineered TCRs overcome the limitations of naturally occurring cancer-antigen specific TCRs which are typically of extremely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcfa9d0de931972c4a382e271ce28438
https://doi.org/10.1158/1538-7445.am2014-2801
https://doi.org/10.1158/1538-7445.am2014-2801
Autor:
Miguel Maroto, Karen Howe, Joanna E. Brewer, Tiago Ferronha, Bent K. Jakobsen, Zoltan Ferjentsik, Gwendolyn Binder-Scholl, Bruno Laugel, Alexandra Sevko
Publikováno v:
Cancer Research. 76:2281-2281
The DNA methyl transferase inhibitors 5-aza-2’-deoxycytidine (decitabine or DECI) and 5-azacytidine (azacitidine or AZA) have recently been approved for the treatment of a variety of hematologic malignancies. These cytidine analogues remove repress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85199c07f1e93c2edb74e9d94d2edf88
https://doi.org/10.1158/1538-7445.am2016-2281
https://doi.org/10.1158/1538-7445.am2016-2281
Autor:
Jessie Gavarret, Rebecca Dennis, Steven M. Dunn, Ruth Moysey, Penio Todorov, Bent K. Jakobsen, Nicholas J. Pumphrey, Andy D. Johnson, Yi Li, Katherine Adams, Deborah H. Sutton, Samantha Paston, Emma Baston, Annelise Vuidepot, Rebecca Ashfield, Joanna E. Brewer, Nikolai Lissin, Brian Cameron, Malkit Sami, Fang Yuan
Publikováno v:
Proteincell. 1(12)
Using directed mutagenesis and phage display on a soluble fragment of the human immunoglobulin super-family receptor ILT2 (synonyms: LIR1, MIR7, CD85j), we have selected a range of mutants with binding affinities enhanced by up to 168,000-fold toward
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f297dd996a43e36047a2aabe9cb616e6
https://pubmed.ncbi.nlm.nih.gov/21213105
https://pubmed.ncbi.nlm.nih.gov/21213105
Autor:
Sunita Philip, Karen Dengel, Minnal Gupta, Alan D. Bennett, Tatiana Mikheeva, Carl H. June, Helen K. Tayton-Martin, Edward A. Stadtmauer, Bent K. Jakobsen, Jeffrey Finkelstein, Andrew B. Gerry, Ashraf Z. Bados, Lilliam Ribeiro, Joanna E. Brewer, Dan T. Vogl, Elizabeth Veloso, Bruce L. Levine, Saul Yanovich, Zhaohui Zheng, Gorgun Akpek, Kelly-Marie Betts, Irina Kulikovskaya, Gwendolyn Binder-Scholl, Erica Suppa, Naseem Kerr, Michael Kalos, Sandra Westphal, Aaron P. Rapoport, Brendan M. Weiss, Dominic P. Smethurst, Nick Pumphrey
Publikováno v:
Cancer Research. 73:4575-4575
Background: Adoptive immunotherapy for cancer has been limited by lack of antigen specificity, low levels of target expression, and failure to break self-tolerance. We are conducting an early phase clinical trial (NCT01352286) attempting to overcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb16aad0fd5ed71752e1b1a42253569d
https://doi.org/10.1158/1538-7445.am2013-4575
https://doi.org/10.1158/1538-7445.am2013-4575